Role of the CCR5 delta 32 allele in resistance to HIV-1 infection in west Africa.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Role of the CCR5 delta 32 allele in resistance to HIV-1 infection in west Africa.

J Hum Virol. 1998 Nov-Dec;1(7):469-74. Unique Identifier : AIDSLINE MED/99211172
Kokkotou E; Philippon V; Gueye-Ndiaye A; Mboup S; Wang WK; Essex M; Kanki P; Department of Immunology and Infectious Diseases, Harvard School; of Public Health, Boston, Massachusetts 02115-6017, USA.

Abstract: OBJECTIVE: To determine the frequency of the mutant CCR5 delta 32 allele in high-risk HIV-seronegative Africans as compared with the general African population, and to assess its in vitro protective efficacy against HIV-1 infection. STUDY DESIGN: In the homozygous form, the CCR5 delta 32 allele confers resistance to macrophage-tropic (M-tropic) strains of HIV-1. Assuming that genetic characteristics favoring HIV resistance would prevail in a high-risk HIV-seronegative population, we examined the CCR5 genotypes of female commercial sex workers (CSWs) from Dakar, Senegal, who have remained uninfected for an elongated period. METHODS: The CCR5 genetic profile of study participants was determined by polymerase chain reaction (PCR) amplification of genomic DNA followed by sequencing. Peripheral blood mononuclear cells (PBMCs) were infected with different strains of HIV-1 and monitored by p24 enzyme-linked immunosorbent assay (ELISA). RESULTS: We confirmed the presence of two CCR5wt/delta 32 genotypes among 139 individuals (1.44%). PBMCs from these 2 heterozygous individuals were also found to be less susceptible to in vitro infection by an M-tropic HIV-1 primary isolate. CONCLUSIONS: Evidence was found of an increased prevalence of the CCR5wt/delta 32 genotype in a high-risk HIV-seronegative cohort in West Africa. Furthermore, reduced susceptibility to HIV-1 infection among heterozygous individuals supports a role for 32-bp CCR5 deletion in HIV-1 resistance.

Keywords: JOURNAL ARTICLE Acquired Immunodeficiency Syndrome/GENETICS/*VIROLOGY *Alleles Cohort Studies Comparative Study Female Follow-Up Studies Genotype Human HIV Seronegativity/*GENETICS *HIV-1 Polymerase Chain Reaction Prostitution Receptors, CCR5/*GENETICS Risk Factors Senegal Support, Non-U.S. Gov't Support, U.S. Gov't, Non-P.H.S.
990730
A9971130

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .